Patient selection for immunotherapy in head and neck cancer - Authors' reply
Lancet Oncol
.
2021 Jul;22(7):e291-e292.
doi: 10.1016/S1470-2045(21)00339-9.
Authors
Nancy Y Lee
1
,
Robert L Ferris
2
,
Steven De Beukelaer
3
,
Ezra Cohen
4
Affiliations
1
Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: leen2@mskcc.org.
2
UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
3
Pfizer, Zürich, Switzerland.
4
Moores Cancer Center, UC San Diego Health, La Jolla, CA, USA.
PMID:
34197753
DOI:
10.1016/S1470-2045(21)00339-9
No abstract available
Publication types
Letter
Comment
MeSH terms
Head and Neck Neoplasms* / therapy
Humans
Immunologic Factors
Immunotherapy / adverse effects
Patient Selection
Substances
Immunologic Factors